Using a CMV vaccine to boost CD19 CAR T cells against B-cell lymphoma
CMV-specific CD19 CAR T cells amplified in vivo using CMV Triplex vaccine for B-NHL
Adults with relapsed or refractory B-cell non-Hodgkin lymphoma would receive CD19 CAR T cells made from CMV-targeted T cells plus a CMV vaccine to help those cells expand and stay active in the body.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Beckman Research Institute/city of Hope NIH-funded |
| Lab location | 1 site (Duarte, United States) |
| Project ID | NIH-11238428 on NIH RePORTER |
What this research studies
You would have your immune T cells selected for reactivity to CMV and then modified to carry a CD19 receptor that targets B-cell lymphoma. Those engineered, bi-specific CAR T cells would be infused back into you. After infusion, you would get the Triplex CMV vaccine to stimulate the CMV-specific feature of the CAR T cells so they grow and stay functional in your body. The vaccine Triplex has already been shown to be safe and strongly boost CMV-directed immune responses in earlier trials.
Who could benefit from this research
Good fit: Adults (21+) with relapsed or refractory B-cell non-Hodgkin lymphoma who are eligible for autologous CD19 CAR T-cell therapy would be the intended candidates.
Not a fit: People who are not eligible for CAR T treatment, have different types of cancer, or have medical conditions that prevent receiving cellular therapy or vaccination are unlikely to benefit.
Why it matters
Potential benefit: If successful, this approach could make CAR T therapy last longer and produce more durable remissions for people with B-cell NHL.
How similar studies have performed: Standard CD19 CAR T therapy can cure some patients but often fails because cells don't persist, and while the Triplex CMV vaccine has been safe and immunogenic in earlier trials, combining CMV-specific T cells with a CAR is a novel strategy.
Where this research is happening
Duarte, United States
- Beckman Research Institute/city of Hope — Duarte, United States (Active)
Researchers
- Principal investigator: Wang, Xiuli — Beckman Research Institute/city of Hope
- Study coordinator: Wang, Xiuli
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.